NCT05694975

Efficacy of Megadose Vitamin C in Severe and Critical Ill COVID-19 Patients.

Clinical Efficacy of Megadose Vitamin C in Severe and Critical Ill COVID-19 Patients (CEMVISCC): A Multicenter, Randomized, Single-blind, Placebo-controlled Clinical Trial

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 608 (estimated)
• Sponsor: Zhujiang Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main aim is to determine whether vitamin C can reduce 28-day all-cause mortality or persistent organ dysfunction compared with placebo in patients with severe and critical ill COVID-19 patients. Participants will randomly receive HIVC or placebo for 4 days once enrolled. The primary outcome is a composite of death or persistent organ dysfunction (defined as dependency on vasopressors, mechanical ventilation, or CRRT) at day 28 after randomization.

Conditions

• Vitamin C
• COVID-19 Pneumonia

Interventions

Type	Name	Description
DRUG	Vitamin C	The total dosage of vitamin C for the treatment group is 24 g per day.
DRUG	Placebo	The total dosage of placebo(5% glucose) for the control group is 24 g per day.

Timeline

• Start date: 2023-01-13
• Primary completion: 2023-04-01
• Completion: 2023-06-01
• First posted: 2023-01-23
• Last updated: 2023-01-23

Locations

4 sites across 1 country: China